Stockreport

Kyverna Therapeutics: Miv-Cel Delivers Breakthrough Data In Stiff Person Syndrome [Seeking Alpha]

Kyverna Therapeutics, Inc.  (KYTX) 
PDF KYTX's Miv-cel achieved significant clinical improvements and eliminated immunotherapy dependence, with a favorable safety profile and no high-grade CRS or ICANS events [Read more]